Global Breathing Disorders & Treatment Market 2020 (Includes Business Impact of COVID-19)

                                          
The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

In August 2020,
Vertex Pharmaceuticals (Ireland) Limited received marketing authorization valid throughout the European Union for Kaftrio which is is a medicine used to treat patients aged 12 years and above who have cystic fibrosis, an inherited disease that has severe effects on the lungs, the digestive system and other organs. Kaftrio is an effective treatment for patients with cystic fibrosis who have two F508del mutations or one F508del and one MF mutation. Two of the active substances in Kaftrio, elexacaftor and tezacaftor, increase the number of CFTR proteins on the cell surface and the other, ivacaftor, improves the activity of the defective CFTR protein. These actions combine to make lung mucus and digestive juices less thick, thereby helping to relieve symptoms of the disease. Both are groups with a high unmet medical need. Patients with one F508del mutation plus other mutations were not covered in the studies, and although the company submitted some data on use in such patients, further data was considered necessary to support authorisation in these groups. In terms of safety, Kaftrio was well tolerated. Therefore, the European Medicines Agency decided that Kaftrio’s benefits are greater than its risks and it can be authorised for use in the EU.

The global Breathing Disorders & Treatment market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2029, growing at a CAGR of xx% during 2021-2029.

This report focuses on Breathing Disorders & Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Breathing Disorders & Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

 	
AstraZeneca
 	
Boehringer
 	
GSK
 	
Merck
 	
Roche
 	
Novartis
 	
Abbott
 	
Actavis
 	
Afferent Pharmaceuticals
 	
Alere
 	
Almirall
 	
Amgen
 	
AptarGroup
 	
Astellas
 	
Aurobindo
 	
Axis-Shield
 	
Baxter
 	
Bayer
 	
Biogen
 	
Biotest
 	
Bristol-Myers Squibb
 	
Chiesi Farmaceutici
 	
Cipla
 	
Cytos
 	
Dainippon Sumitomo
 	
Dr. Reddys Laboratories

Segment by Breathing Disorders

 	
Asthma
 	
COPD
 	
Allergic rhinitis
 	
Pulmonary hypertension
 	
Cystic fibrosis
 	
Idiopathic pulmonary fibrosis

Segment by Route of Dosage

 	
Oral
 	
Inhable
 	
Others